Physician profile
Thomas Plate
NPI 1558865956
$15,138.34
in general payments reported to CMS, 2019-2025
16 companies · $9,089 in 2025
The $9,089 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2024: $5,925 · 2025: $9,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,524.00 |
| Food and Beverage | $2,490.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12,478.47 | 2024-2025 | |
| Daiichi Sankyo INC. | $750.31 | 2024-2025 | Vanflyta, Enhertu, Datroway |
| Glaxosmithkline, LLC. | $571.72 | 2021-2025 | Ojjaara, Jemperli |
| Janssen Biotech, INC. | $192.00 | 2024-2025 | Carvykti, Rybrevant, Darzalex |
| Regeneron Healthcare Solutions, INC. | $146.75 | 2024-2025 | Libtayo |
| Janssen Scientific Affairs, LLC | $144.53 | 2024 | Rybrevant |
| Pfizer INC. | $138.40 | 2024 | |
| Adaptive Biotechnologies Corporation | $131.72 | 2024 | Clonoseq |
| Amgen INC. | $123.71 | 2025 | Blincyto |
| Recordati_rare_diseases_inc. | $123.21 | 2025 | Sylvant |
| Agios Pharmaceuticals, INC. | $121.82 | 2024 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $100.98 | 2025 | Monoferric |
| Novartis Pharmaceuticals Corporation | $49.90 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $27.89 | 2025 | Enhertu |
| Genentech USA, INC. | $22.81 | 2024 | Venclexta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14.12 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Plate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.